Lates News

Pfizer was basically flat in early trading on Tuesday, after the company reported better-than-expected third-quarter results, raised its full-year adjusted EPS guidance to $3.00-3.15, and reiterated its cost-cutting targets amid declining sales of its COVID-19 related products.